Circulating FABP-4 Levels in Patients with Atherosclerosis or Coronary Artery Disease: A Comprehensive Systematic Review and Meta-Analysis
Cardiovascular Therapeutics · 17.11.2023 · 2023 · 1-10
DOI: 10.1155/2023/1092263 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Cardiovascular Therapeutics, erschienen am 17.11.2023. Verfasst von Narges Jalilian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biochemistry, Faculty of Medical Sciences, Ilam University of Medical Sciences, Ilam, Iran. Hauptthemen laut MEDLINE: Atherosclerosis, Coronary Artery Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ilam University of Medical Sciences.
Abstract (Originalsprache)
Background
Cardiovascular diseases (CDs), notably coronary artery disease (CAD) due to atherosclerosis, impose substantial global health and economic burdens. Fatty acid-binding proteins (FABPs), including FABP-4, have been recently linked to CDs. This study conducted a systematic review and meta-analysis to examine FABP-4 levels in CAD and atherosclerosis patients, exploring their potential links to these conditions.
Methods
A systematic review and meta-analysis were done based on the PRISMA guideline. The international databases including Medline, Embase, Cochrane Library, Scopus, Web of Science, and UpToDate were searched to find all related studies on the effect of FABP-4 on patients with CAD or atherosclerosis which were published till June 2022 without language restriction. The Cochran’s Q -test and I 2 statistic were applied to assess heterogeneity, a random effect model was used to estimate the pooled standardized mean difference (SMD), a metaregression method was utilized to investigate the factors affecting heterogeneity between studies, and Egger’s test was used to assess the publication bias.
Results
Of 1051 studies, 9 studies with a sample size of 2327 were included in the systematic review and meta-analysis. The level of circulating FABP-4 in the patient groups was significantly higher than in the control groups ( SMD = 0.60 (95% CI: 0.30 to 0.91, I 2 : 91.47%)). The SMD in female and male patients were 0.26 (95% CI: 0.01 to 0.52, I 2 : 0%) and 0.22 (95% CI: 0.08 to 0.35, I 2 : 44.7%), respectively. There was considerable heterogeneity between the studies. The countries had a positive relationship with heterogeneity ( coefficient = 0.29 , p < 0.001 ); but BMI, lipid indices, gender, study design, and type of kit had no effect on the heterogeneity. No publication bias was observed ( p : 0.137).
Conclusion
In summary, this meta-analysis revealed elevated circulating FABP-4 levels in CDs, suggesting its potential as a biomarker for these conditions. Further research is warranted to explore its clinical relevance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Biochemistry, Faculty of Medical Sciences, Ilam University of Medical Sciences, Ilam, Iran.
- Student Research Committee, Ilam University of Medical Sciences, Ilam, Iran.
- Department of Epidemiology, Faculty of Health, Ilam University of Medical Sciences, Ilam, Iran.
- Health and Environment Research Center, Ilam University of Medical Sciences, Ilam, Iran.
- Department of Health Education and Promotion, Faculty of Health, Ilam University of Medical Sciences, Ilam, Iran.
- Feinberg Cardiovascular and Renal Research Institute, Northwestern University, Chicago, IL, USA.
ORCID-Profile: Reza Pakzad, Salar Bakhtiyari
Förderung
- Ilam University of Medical Sciences
Zitieren
APA
Jalilian, N., Pakzad, R., Shahbazi, M., Edrisi, S. R., Haghani, K., Jalilian, M., & Bakhtiyari, S. (2023). Circulating FABP-4 Levels in Patients with Atherosclerosis or Coronary Artery Disease: A Comprehensive Systematic Review and Meta-Analysis. Cardiovascular Therapeutics, 2023, 1-10. https://doi.org/10.1155/2023/1092263
Vancouver
Jalilian N, Pakzad R, Shahbazi M, Edrisi SR, Haghani K, Jalilian M, et al. Circulating FABP-4 Levels in Patients with Atherosclerosis or Coronary Artery Disease: A Comprehensive Systematic Review and Meta-Analysis. Cardiovascular Therapeutics. 2023;2023:1-10. doi:10.1155/2023/1092263
BibTeX
@article{Jalilian2023,
author = {Jalilian, Narges and Pakzad, Reza and Shahbazi, Mahdi and Edrisi, Seyyed-Reza and Haghani, Karimeh and Jalilian, Mohsen and Bakhtiyari, Salar},
title = {Circulating FABP-4 Levels in Patients with Atherosclerosis or Coronary Artery Disease: A Comprehensive Systematic Review and Meta-Analysis},
journal = {Cardiovascular Therapeutics},
year = {2023},
volume = {2023},
pages = {1--10},
doi = {10.1155/2023/1092263}
}
EUVIMED